EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Treatment strategies for advanced and recurrent endometrial cancer using immune checkpoint inhibitors

Ami Jo, Tadahiro Shoji, Haruka Otsuka, Marina Abe, Shunsuke Tatsuki, Yohei Chiba, Sho Sato, Eriko Takatori, Yoshitaka Kaido, Takayuki Nagasawa, Masahiro Kagabu, Tsukasa Baba

International Journal of Clinical Oncology · 2025

DOI: 10.1007/s10147-024-02689-8 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Clinical Oncology, 2025. Verfasst von Ami Jo und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Iwate Medical University School of Medicine, 2-1-1, Idaidori, Yahaba, Iwate, 028-3695, Japan. Hauptthemen laut MEDLINE: Endometrial Neoplasms, Immune Checkpoint Inhibitors, Neoplasm Recurrence, Local, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 45 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Doxorubicin + cisplatin and paclitaxel + carboplatin are standard chemotherapy regimens for endometrial cancer. The development of PD-1 and PDL-1 antibody drugs has led to the use of these agents for endometrial cancer in other countries. The KEYNOTE-775 trial for advanced or recurrent endometrial cancer demonstrated the benefits of pembrolizumab and lenvatinib combination therapy, and the results of this trial led to the approval of its coverage for recurrent cancer by the Japanese health insurance system. Currently, treatment with immune checkpoint inhibitors is transitioning from second-line to first-line therapy. In a global randomized phase III study, the drugs dostarlimab, durvalumab, and atezolizumab, which are not yet approved in Japan, showed better results in the study arms than in the control arm. Additionally, biomarkers have been developed for endometrial cancer, enabling gynecologists to pursue treatment options based on the biomarkers detected for better treatment outcomes. In this article, we review the clinical trials of immune checkpoint inhibitors for advanced or recurrent endometrial cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Endometrial NeoplasmsImmune Checkpoint InhibitorsNeoplasm Recurrence, LocalAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleRandomized Controlled Trials as TopicBiomarkers, Tumor

Stichwörter der Autor:innen

ChemotherapyClinical trialsEndometrial cancerImmune checkpoint inhibitorsImmunotherapy

Substanzen

Immune Checkpoint InhibitorsBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Iwate Medical University School of Medicine, 2-1-1, Idaidori, Yahaba, Iwate, 028-3695, Japan.
  • Department of Obstetrics and Gynecology, Iwate Medical University School of Medicine, 2-1-1, Idaidori, Yahaba, Iwate, 028-3695, Japan. tshoji@iwate-med.ac.jp.

Zitieren

APA

Jo, A., Shoji, T., Otsuka, H., Abe, M., Tatsuki, S., Chiba, Y., Sato, S., Takatori, E., Kaido, Y., Nagasawa, T., Kagabu, M., & Baba, T. (2025). Treatment strategies for advanced and recurrent endometrial cancer using immune checkpoint inhibitors. International Journal of Clinical Oncology. https://doi.org/10.1007/s10147-024-02689-8

Vancouver

Jo A, Shoji T, Otsuka H, Abe M, Tatsuki S, Chiba Y, et al. Treatment strategies for advanced and recurrent endometrial cancer using immune checkpoint inhibitors. International Journal of Clinical Oncology. 2025. doi:10.1007/s10147-024-02689-8

BibTeX
@article{Jo2025,
  author = {Jo, Ami and Shoji, Tadahiro and Otsuka, Haruka and Abe, Marina and Tatsuki, Shunsuke and Chiba, Yohei and Sato, Sho and Takatori, Eriko and Kaido, Yoshitaka and Nagasawa, Takayuki and Kagabu, Masahiro and Baba, Tsukasa},
  title = {Treatment strategies for advanced and recurrent endometrial cancer using immune checkpoint inhibitors},
  journal = {International Journal of Clinical Oncology},
  year = {2025},
  doi = {10.1007/s10147-024-02689-8}
}
Kostenlos starten →